Statistics for TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT
Total visits
| views | |
|---|---|
| TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT | 64 |
Total visits per month
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
File Visits
| views | |
|---|---|
| TRIB2 confers resistance to anti-cancer therapy by activating the serine threonine protein kinase AKT.pdf(legacy) | 82 |
| TRIB2 confers resistance to anti-cancer therapy by activating the serine threonine protein kinase AKT.pdf | 10 |
Top country views
| views | |
|---|---|
| United States | 48 |
| Portugal | 13 |
| China | 1 |
| South Korea | 1 |
| Russia | 1 |